New LaunchNov 2, 2026, 07:01 AM
Eton Pharmaceuticals Launches ET-900 Program for Infantile and Epileptic Spasms
AI Summary
Eton Pharmaceuticals, Inc. has launched a new development program, ET-900, to evaluate mecasermin injection for the treatment of infantile and epileptic spasms. The company has secured a license from Baylor College of Medicine for patent rights related to insulin-like growth factor 1 (IGF-1) for spasm treatment. An Investigational New Drug (IND) application has been submitted to the FDA for an investigator-sponsored Phase 2 clinical study, with initial patient dosing anticipated in the first quarter of 2027. Preclinical data suggests IGF-1 therapy can reduce spasms.
Key Highlights
- Eton Pharmaceuticals announces ET-900 program for infantile and epileptic spasms.
- Licensed patent rights from Baylor College of Medicine for IGF-1 use in spasms.
- Investigational New Drug (IND) application submitted to FDA for Phase 2 study.
- First patient dosing for the Phase 2 study targeted for Q1 2027.
- Preclinical research showed IGF-1 therapy reduced spasms in animal models.
- Eton retains commercial rights to ET-900.
Price Impact
More from ETON